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MT1-MMPCardiac myoﬁbroblasts are pivotal to adaptive remodelling after myocardial infarction (MI). These normally
quiescent cells invade and proliferate as a wound healing response, facilitated by activation of matrix
metalloproteinases, particularly MMP-2. Following MI these reparative events occur under chronically
hypoxic conditions yet the mechanisms by which hypoxia might modulate MMP-2 activation and cardiac
myoﬁbroblast invasion have not been investigated. Human cardiac myoﬁbroblasts cultured in collagen-
supplemented mediumwere exposed to normoxia (20% O2) or hypoxia (1% O2) for up to 48 h. Secreted levels
of total and active MMP-2 were quantiﬁed using gelatin zymography, TIMP-2 and membrane-associated
MT1-MMP were quantiﬁed with ELISA, whole cell MT1-MMP by immunoblotting and immunocytochemistry
and MT1-MMP mRNA with real-time RT-PCR. Cellular invasion was assessed in modiﬁed Boyden chambers
and migration by scratch wound assay.
In the human cardiac myoﬁbroblast, MT1-MMP was central to MMP-2 activation and activated MMP-2
necessary for invasion, conﬁrmed by gene silencing. MMP-2 activation was substantially attenuated by
hypoxia (Pb0.001), paralleled by inhibition of myoﬁbroblast invasion (Pb0.05). In contrast, migration was
independent of either MT1-MMP or MMP-2. Reduced membrane expression of MT1-MMP (Pb0.05) was
responsible for the hypoxic reduction of MMP-2 activation, with no change in either total MMP-2 or TIMP-2.
In conclusion, hypoxia reduces MMP-2 activation and subsequent invasion of human cardiac myoﬁbroblasts
by reducing membrane expression of MT1-MMP and may delay healing after MI. Regulation of these MMPs
remains an attractive target for therapeutic intervention.© 2009 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Fibroblasts account for up to two-thirds of the total cell number in
the normal human heart [1] and maintain the integrity of myocardial
structure through controlled proliferation and extracellular matrix
(ECM) turnover [2,3]. Adverse remodelling following myocardial
infarction (MI) is characterised by myocyte death, hypertrophy of
surviving myocytes, proliferation, migration and invasion of cardiac
myoﬁbroblasts and ﬁbrosis [3–5]. An important part of this process is
the transformation of normally quiescent cardiac ﬁbroblasts into the
proliferative and invasive myoﬁbroblast phenotype that can alter the
structure of the cardiac interstitium through increased expression and
activation of matrix-degrading metalloproteinases (MMPs), particu-d Neuronal Remodelling, Leeds
University of Leeds, Leeds LS2
t.
-NC-ND license.larly the gelatinases MMP-2 and MMP-9 [6,7]. Gelatinase activation is
a prerequisite for both proliferation and invasion in vivo and is
required to promote myocardial infarct healing and adaptive remo-
delling. However, in the long-term this can lead to adverse myocardial
remodelling characterised by impaired contractile function and
ﬁbrosis.
Unlike MMP-9, which is primarily regulated at the transcriptional
level, MMP-2 is constitutively expressed by cardiac myoﬁbroblasts
and secreted in a latent form (proMMP-2). Activation of proMMP-2
takes place at the cell membrane and requires the participation of
both membrane-type 1 matrix metalloproteinase (MT1-MMP) and
tissue inhibitor of metalloproteinases-2 (TIMP-2) in cancer cells [8].
MT1-MMP is itself expressed in a latent form and processed
intracellularly to its active species by furin, a proprotein convertase
that cleaves precursor proteins to their biologically active state [9].
Generation of active MT1-MMP and its transfer to the cell membrane
is a critical step in MMP-2 activation [8] and, together with TIMP-2,
facilitates membrane binding of proMMP-2 to MT1-MMP. Although
the main role of TIMP-2 is that of physiological inhibition of MMP-2
392 K. Riches et al. / Journal of Molecular and Cellular Cardiology 47 (2009) 391–399andMT1-MMP by post-translational regulation [10], it is also essential
for cell membrane binding of proMMP-2. This binding in turn
promotes activation of proMMP-2 which facilitates ECM degradation
[11].
Acute coronary events such as MI lead to profound myocardial
injury and are inevitably associatedwith periods of inadequate oxygen
supply (hypoxia) to the myocardium. Hypoxia itself is a major cue for
tissue remodelling in the cardiovascular system, in part via MMP
activation [12,13]. Indeed, distinct responses in different cell types in a
variety of species have been shown to be induced as a result of hypoxic
insult. Typically, hypoxia has been reported to increase cellular
activation of MMP-2 as demonstrated in monkey endothelial cells
[14], rat cardiac ﬁbroblasts [15] and human HT-1080 ﬁbrosarcoma
cells [16]. Interestingly however, although chronic hypoxia increased
MMP-2 secretion in human endothelial cells, a decrease in its
activation was observed [17]. Similarly, an inhibitory effect of chronic
hypoxia on MMP-2 activation has been documented in human
endometrial stromal cells [17,18] and proximal tubular cells [19]. It is
clear therefore, that hypoxia-induced effects on MMP-2 activation are
both species and cell-type speciﬁc and, importantly, the underlying
mechanisms are not consistent. Since any changes to the regulation of
matrix deposition and degradation in the myocardium have the
potential to create deleterious effects on myocardial function, the
present study was designed to investigate speciﬁcally the inﬂuence of
chronic hypoxia on collagen-induced MMP-2 activation and invasion
of human cardiac myoﬁbroblasts.
2. Materials and methods
2.1. Reagents
All cell culture reagents were purchased from Invitrogen (Paisley,
UK), except foetal calf serum (FCS) that was from Biosera (Ringmer,
East Sussex, UK). Invasion and migration assay chambers and inserts
were from BD Biosciences (Oxford, UK). Real-time PCR reagents were
from Applied Biosystems (www.appliedbiosytems.com).
2.2. Cell culture
Biopsies of human atrial appendage were obtained from patients
undergoing elective coronary artery bypass grafting (CABG). Ethical
committee approval and informed patient consent were obtained and
the investigation conformed to the principles outlined in the
Declaration of Helsinki. Primary cultures of atrial cardiac myoﬁbro-
blasts were harvested and cultured in full growthmedium (Dulbecco's
Modiﬁed Eagle's Medium (DMEM) supplementedwith 10% FCS, 2 mM
L-glutamine, 100 μg/ml penicillin G, 100 μg/ml streptomycin and
0.25 μg/ml amphotericin) essentially as we have described previously
[20]. Cells were characterised asmyoﬁbroblasts by co-expression ofα-
smooth muscle actin (α-SMA) and vimentin [21,22]. Experiments
were performed on early passage cells (2–5) from different patients.
HT-1080 cells were cultured in ﬁbroblast full growth medium
(DMEM plus 10% FCS) and serially passaged by trypsinisation.
2.3. Collagen supplemented myoﬁbroblast culture
Cardiac myoﬁbroblasts (3×105) were plated in full growth
medium and incubated overnight. Medium was then exchanged for
serum free medium (SFM) for 48 h. Serum-starved cells were
transferred to fresh medium supplemented with 0.5% FCS and
50 μg/ml Type I collagen (Calbiochem) and transferred to humidiﬁed
incubators at 37 °C for 24–48 h in normoxia (5% CO2 in air) or hypoxia
(1% O2, 5% CO2, 94% N2). Type I collagen culture conditions were used
to represent the in vivo environment of cardiac myoﬁbroblasts.
Samples of conditioned media (CM) were collected for zymography
and/or immunoassay (ELISA).2.4. Gelatin zymography
Gelatin zymography and subsequent densitometric analysis were
performed on myoﬁbroblast CM as we have described previously
[23,24]. Optimised loading volumes were determined by serial
dilution of CM to ensure that band intensity was proportional to
MMP-2 zymographic activity. CM from HT-1080 cells (a human
ﬁbrosarcoma cell line that constitutively secretes MMP-2) [16] was
included on each gel as a positive control.
2.5. ELISA
MMP-2 or TIMP-2 protein levels in CM were quantiﬁed by ELISA
(R&D Systems, Abingdon, UK). Membrane-bound MT1-MMP was
measured by ELISA (Amersham Biosciences, Amersham, UK) of
membrane fractions prepared following 15 min exposure of cells to
2 ml extraction buffer (50 mM Tris–HCl, pH 7.6; 1.5 mM NaCl; 0.5 mM
CaCl2; 1 μM ZnCl2; 0.01% Brij-35; 0.25% Triton X-100) at 4 °C.
2.6. Real-time RT-PCR
Myoﬁbroblasts were cultured in collagen-supplemented medium in
normoxia/hypoxia for 24–48 h. RNA extraction and reverse transcrip-
tion were performed as we described previously [25]. Real-time PCR
with humanMT1-MMP (Hs00237119_m1) primers and Taqman probes
was performed using the Applied Biosystems 7500 Real-Time PCR
System. Data are expressed as a percentage of β-actin mRNA levels
(Hs99999903_m1 primers) using the formula 2−ΔCT×100.
2.7. Whole cell MT1-MMP levels
MT1-MMP levels within the whole cell were analysed by
immunocytochemistry and immunoblotting. For ﬂuorescence immu-
nocytochemistry, cells were ﬁxed in 4% paraformaldehyde and stained
using a previously described protocol [26]. For immunoblotting, non-
reduced cell lysates were prepared by scraping into extraction buffer
(50 mM Tris–HCl pH 7.5, 150 mM NaCl, 1 mM CaCl2, 0.05% Brij-35),
sonicating 6×10 s (4 °C) and centrifugation for 15min (8000 ×g, 4 °C)
to pellet cellular debris. Lysateswere subsequently electrophoresed on
a 7.5% SDS-PAGE gel, transferred to PVDF membrane and visualised
using MT1-MMP antibody (ab38971; AbCam, Cambridge, UK) and
enhanced chemiluminescence.
2.8. Inhibition of lysosomal degradation
Cells were cultured in normoxia/hypoxia in 24-well plates in
collagen-supplemented media with a range of concentrations of the
lysosomal inhibitor baﬁlomycin-A1 (Sigma-Aldrich, Poole UK). Fol-
lowing 48 h incubation, CM was collected and MMP-2 activation
analysed by gelatin zymography.
2.9. Cardiac myoﬁbroblast phenotype
Cells cultured for 48 h in normoxia/hypoxia in 8-well chamber
slides, were ﬁxed and stainedwith antibodies toα-SMA and vimentin,
ﬁrmly establishing their myoﬁbroblast phenotype in these conditions
without additional transformation, as previously described [22].
2.10. Proliferation assays
Proliferation assays were performed as we described previously
[22]. Cardiac myoﬁbroblasts were cultured in parallel in normoxia and
hypoxia in medium containing 0.5% and 10% FCS. Cell numbers were
monitored over a 7-day period.
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Invasion assays were performed essentially as we described
previously [24] using a modiﬁed Boyden chamber technique with
Matrigel basement membrane matrix coated membranes (BD Bios-
ciences, Oxford, UK). Chemoattractant (2.5% FCS in DMEM) was
loaded into the lower chamber and cardiac myoﬁbroblasts were cast
in Type I collagen gels in the upper chamber (1×105 cells) in SFM
supplemented with 0.25% bovine serum albumin (BSA). After a 48-h
incubation period in normoxic or hypoxic conditions, processing and
evaluation were performed [24]. For gene silencing studies, trans-
fectedmyoﬁbroblasts were incubated for 24 h inmedia supplemented
with 0.4% FCS prior to the assay. After 22 h, cell supernatants were
collected from the upper chambers for analysis by gelatin zymography
and invasion quantiﬁed by counting the invaded cells in ten random
high power ﬁelds (×400) for each membrane [24].
2.12. Wound scratch migration assays
Wound scratch migration assays were performed essentially as
described previously [27] with minor modiﬁcations. A single linear
wound was madewith a 10 ml pipette tip in conﬂuent cultures of 48 h
serum-starved cardiacmyoﬁbroblasts, thenwashed gently with PBS to
remove cellular debris. The cells were transferred to fresh DMEM
supplemented with 0.5% FCS and 50 μg/ml Type I collagen, and
incubated at 37 °C under normoxic and hypoxic conditions. After 48 h
cells were photographed using phase contrast microscopy (×40
magniﬁcation). The number of cells migrating beyond a marker
500 μm from the wound edge was counted.
2.13. Transfection of siRNA oligonucleotides
Cardiac myoﬁbroblasts (3×105) were incubated overnight in
medium supplemented with 0.4% FCS, prior to transfection with
siRNA targeting MMP-2 (5′-CGGACAAAGAGUUGGCAGU-3′, 200 nM,
Eurogentec) or MT1-MMP (5′-GGAAUGAGGAUCUGAAUGG-3′, 50 nM,Fig. 1. Effect of collagen and hypoxia on MMP-2 activation in cardiac myoﬁbroblasts and
myoﬁbroblasts cultured without (−) or with (+) 50 μg/ml collagen in normoxia (20% O2) o
expressed relative to cells cultured in collagen and normoxia. ⁎⁎⁎Pb0.001 (n=6). (C) Re
conditions (note two bands showing cleavage products). (D) Densitometric quantiﬁcation oAmbion) using Lipofectamine 2000 (Invitrogen), or mock transfected
(Lipofectamine without siRNA) as we have previously described
[25,28]. Gelatin zymography and ELISA were performed to conﬁrm
efﬁcient silencing of MMP-2 and MT1-MMP respectively.
2.14. Statistical analysis
All results are expressed as mean±SEM with n representing the
number of experiments on cells from different patients. Differences
between treatment groups were analysed using paired ratio t-tests or
one-way repeated measures ANOVA with a Bonferroni post-hoc test
(GraphPad Prism software, www.graphpad.com). Pb0.05 was con-
sidered statistically signiﬁcant.
3. Results
3.1. Type I collagen induces MMP-2 activation that is attenuated by
chronic hypoxia
Myoﬁbroblasts cultured in the presence of Type I soluble collagen
under normoxic conditions showed signiﬁcant activation of MMP-2
compared with cells cultured in the absence of collagen (Fig. 1A), as
evidenced by the appearance of a lower molecular weight zymogen
band (62 kDa) in addition to the 72 kDa proprotein. There were no
differences in secreted levels of total MMP-2 between cells cultured in
the absence or presence of collagen (data not shown). After exposure
to chronic hypoxia (1% O2, 48 h) collagen-induced MMP-2 activation
was signiﬁcantly and consistently attenuated by ∼50% (Figs. 1A, B).
This was not the result of cell death in hypoxia, since cell numbers
were similar over 7 days (Fig. 4F), conﬁrming that differences inMMP-
2 activation were not attributable to variations in cell number. We
repeated these experiments using the human ﬁbrosarcoma cell line
HT-1080 in which hypoxic regulation of MMP-2 secretion and
activation has previously been characterised [16]. In marked contrast
to the myoﬁbroblasts, but in agreement with this previous report, HT-
1080 cells exhibited a signiﬁcant increase in MMP-2 activationHT-1080 cells. (A) Representative zymography of conditioned media collected from
r hypoxia (1% O2) for 48 h. (B) Densitometric quantiﬁcation of active MMP-2. Data are
presentative zymogram of HT-1080 conditioned media under the same experimental
f combined intermediate and fully active MMP-2 ⁎⁎Pb0.01 (n=5).
Fig. 2. Effect of hypoxia on total MMP-2, TIMP-2 and MT1-MMP expression. Cardiac myoﬁbroblasts were cultured with collagen under normoxia or hypoxia for 48 h. Conditioned
media were analysed by ELISA for (A) total (pro- and active) MMP-2 or (B) total TIMP-2. NS=not signiﬁcant (n=5). (C) Cells were cultured with collagen under normoxia or
hypoxia for 24 h before extracting RNA and performing real-time RT-PCR. Data shows quantiﬁcation of MT1-MMPmRNA levels as a percentage of β-actin levels. NS=not signiﬁcant
(n=5). (D) Immunoﬂuorescent detection of MT1-MMP localisation (green) following 48 h of collagen-supplemented culture under normoxic or hypoxic conditions. Nuclei stained
with DAPI (blue). Scale bar=50 μm. (E) Membrane expression of MT1-MMP (ELISA) after 48 h normoxia or hypoxia. ⁎Pb0.05 (n=5). (F) Representative immunoblot of whole cell
MT1-MMP expression in lysates prepared following 48 h of collagen-supplemented culture in normoxia and hypoxia with β-actin as loading control.
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agreement with this same report, an intermediate band of MMP-2
activation (∼68 kDa) was observed in HT-1080 media (Fig. 1C). Thus,
the effects of hypoxia observed in human cardiac myoﬁbroblasts were
markedly different from those seen in HT-1080 cells.
3.2. Hypoxia attenuates MT1-MMP but does not affect TIMP-2 or MMP-2
Activation of MMP-2 at the cell membrane requires formation of a
ternary complex of MT1-MMP, TIMP-2 and proMMP-2 [8]. We
therefore investigated whether the observed reduction in MMP-2
activation in myoﬁbroblasts cultured in hypoxia might be due to
changes in total MMP-2, TIMP-2 and/or MT1-MMP expression.
Densitometric analysis of gelatin zymograms demonstrated no change
in total MMP-2 secretion in response to hypoxia (Fig. 1A), and this was
conﬁrmed by ELISA (Fig. 2A). Similarly, hypoxia had no effect on TIMP-
2 protein levels (Fig. 2B). We next quantiﬁed levels of MT1-MMP
mRNA and, because it is the active form of MT1-MMP that trafﬁcs to
the plasma membrane to facilitate MMP-2 activation [11,29], we also
measured MT1-MMP protein in cell membrane and whole cell
fractions using ELISA and immunoblotting. Hypoxia did not alter
steady-state MT1-MMPmRNA levels (Fig. 2C). Immunocytochemistry
revealed a general diffuse staining within the cytoplasm, with a moreconcentrated localisation of MT1-MMP at the cell periphery in
normoxia. This association with the membrane was not apparent
when cells were cultured under chronically hypoxic conditions (Fig.
2D). In keeping with the immunoﬂuorescence ﬁndings, measurement
of MT1-MMP in cell membrane preparations using ELISA showed a
∼40% reduction under hypoxic conditions (Fig. 2E). Measurement of
total MT1-MMP inwhole cell lysates (ELISA and immunoblotting) also
indicated a ∼40% decrease with hypoxia (Fig. 2F).
3.3. Lysosomal degradation of MT1-MMP is not enhanced by hypoxia
As hypoxia reduced MT1-MMP protein without affecting MT1-
MMP mRNA, we looked for evidence of hypoxia-induced MT1-MMP
degradation. MT1-MMP is degraded by lysosomes [30], therefore cells
were cultured with increasing concentrations of the lysosomal
inhibitor baﬁlomycin-A1 to determine whether the decrease in
MMP-2 activation could be attributable to enhanced degradation of
MT1-MMP. Zymographic analysis of CM from cells cultured in
normoxia revealed that baﬁlomycin-A1 increased activation of
MMP-2 in a concentration-dependent manner (Figs. 3A, B). However,
irrespective of baﬁlomycin-A1 treatment, cells cultured under hypoxic
conditions exhibited attenuation of MMP-2 activation compared with
normoxic counterparts (Figs. 3A, B).
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Cellular invasion requires two distinct phases; degradation of ECM
followed by cellular migration towards a chemotactic stimulus. A 48 h
hypoxic period led to a signiﬁcant inhibition of myoﬁbroblast invasion
of almost 50% compared with normoxic cells (Figs. 4A, B). This was
associated with a corresponding decrease in MMP-2 activation in the
supernatants from cells used in these experiments (Figs. 1A, B).
However, in the wound scratch assay, despite also observing a
consistent inhibition of MMP-2 activation, there was no difference
in cellular migration between the normoxic and hypoxic treatment
groups (Figs. 4C, D). Immunocytochemical analysis of normoxic and
hypoxic cells for the markers α-SMA and vimentin conﬁrmed that the
cells had retained their myoﬁbroblast phenotype (Fig. 4E). These
results together strongly suggest that MMP-2 activation is a
prerequisite for cardiac myoﬁbroblast invasion, but not migration.
3.5. MT1-MMP is required for collagen-stimulated MMP-2 activation and
invasion, but not migration
Since we had demonstrated that hypoxia reduced invasion (but
not migration), and also reduced both MT1-MMP protein levels
together with MMP-2 activity, we sought to establish whether these
effects were sufﬁcient to inhibit myoﬁbroblast invasion. Myoﬁbro-
blasts transfected with siRNA targeting MT1-MMP or MMP-2 were
cultured in collagen for 48 h and supernatants subjected to
zymography. Total MMP-2 was selectively reduced by ∼50% with
MMP-2 gene silencing, but was unaffected by MT1-MMP siRNA (Figs.
5A, B). Cells transfected with MT1-MMP siRNA exhibited a ∼50%
decrease in membrane MT1-MMP expression (Fig. 5C). Importantly,
selective silencing of either MT1-MMP or MMP-2 resulted in a
signiﬁcant reduction in active MMP-2 levels (Fig. 5D), to a levelFig. 3. Effect of lysosomal inhibition onMMP-2 activation. Cells were cultured for 48 h in
normoxia and hypoxia with a range of concentrations of the lysosomal inhibitor
baﬁlomycin-A1. (A) Representative zymography of CM collected from myoﬁbroblasts
culturedwith 50 μg/ml collagen and 0.3–3 nM baﬁlomycin-A1 in normoxia and hypoxia
for 48 h. (B) Densitometric quantiﬁcation of active MMP-2. Data are expressed relative
to cells cultured in vehicle and normoxia. ⁎Pb0.05 for the effect of hypoxia in the
absence of baﬁlomycin-A1 (n=5). ANOVA values: P=0.0263 (normoxia), P=0.0001
(hypoxia).comparable with that observed in myoﬁbroblasts during hypoxic
culture.
The functional roles of bothMT1-MMP andMMP-2were examined
by studying siRNA-treated cells in invasion and migration assays.
Silencing of either MT1-MMP or MMP-2 resulted in decreased cellular
invasion of ∼50% (Fig. 5E). Parallel wound scratch assays revealed no
difference in myoﬁbroblast migration between control and trans-
fected groups, conﬁrming that cell motility per se is independent of
MT1-MMP and MMP-2 activity (Fig. 5F). These observations concur
with our observed effects of hypoxia on cell function, thus conﬁrming
the pivotal role of membrane-associated MT1-MMP activity in the
mechanism of MMP-2 activation and invasion in this cell type.
4. Discussion
This study reveals mechanisms unique to human cardiac myoﬁ-
broblasts of potential clinical signiﬁcance, underscoring the impor-
tance of selecting appropriate experimental models. Cardiac
myoﬁbroblasts reside in a ﬁbrillar collagen matrix in vivo, and we
demonstrate here that collagen-supplemented in vitro cultures
provide an appropriate physiological stimulus for activation of
MMP-2 in human cardiac myoﬁbroblasts. Moreover, myoﬁbroblasts
in culture are phenotypically comparable with their in vivo counter-
parts [29] and similar studies have also been reported for other
ﬁbroblast cultures [31]. We show here that MMP-2 activation is a
prerequisite for cellular invasion, a process fundamental to promotion
of the early, adaptive healing response after myocardial injury and is
attenuated by hypoxia.
Considerable evidence supports a role for MMP-2 and MT1-MMP
in cellular invasion. ProMMP-2 displays a unique cell surface
activation mechanism involving the formation of a trimolecular
complex comprising MT1-MMP, TIMP-2 and proMMP-2 [8–10].
Therefore, MMP-2 activation can be regulated by changes in expres-
sion and/or activation of any of thesemolecules. In marked contrast to
previously published studies using a variety of cell types [14–17,32],
including rat cardiac ﬁbroblasts [15], exposure to chronic hypoxia
signiﬁcantly attenuated MMP-2 activation in human cardiac myoﬁ-
broblasts. These observations cannot be attributed to methodological
variance since, in agreement with the study of Fahling et al. [16], we
also observed a signiﬁcant increase in activation of MMP-2 by hypoxia
in HT-1080 cells. Our ﬁndings for human cardiac myoﬁbroblasts
therefore represent a novel response to hypoxia.
In vitro studies are usually conducted in an atmosphere of 95% air.
This represents an O2 level of 20%; far greater than any cellular
exposure in vivo. Our data emphasise the powerful effects of reducing
O2 levels to those observed in vivo during clinically important insults
such as MI. Clearly, this level of hypoxia has profound effects on
protein expression which can be mediated by numerous transcription
factors including HIF-1, NFκB and CREB [33].
TIMP-2, in addition to its principal role as the naturally-occurring
physiological inhibitor of MMP-2, is also required for its activation,
albeit at lower concentrations [34]. In our present study, although
TIMP-2 was consistently detected, its concentration in conditioned
media of both normoxic and hypoxic myoﬁbroblasts was similar and
therefore changes in TIMP-2 levels could not account for our observed
changes in MMP-2 activation. It is well established that MT1-MMP is
pivotal to MMP-2 activation; however reports are inconsistent with
respect to its modulation under hypoxic conditions. That MT1-MMP
mRNA was unchanged by hypoxia in our study is in agreement with
previous reports [16,32] although both those studies used inherently
invasive cell lines and moreover, both reported increased MMP-2
activation in contrast to our observed decrease. However, other
studies have reported either increased [35] or decreased [17] MT1-
MMP mRNA levels, further emphasising the species and cell-type
speciﬁc response to hypoxia. Here, although MT1-MMP mRNA levels
were not modulated by hypoxia, total levels of protein within the cell
Fig. 4. Effect of hypoxia on cardiac myoﬁbroblast invasion, migration and proliferation. Invasion assays were performed over a 48 h period in normoxia or hypoxia. Membranes were
ﬁxed, stained and cell invasion quantiﬁed by counting 10 high power (×400) ﬁelds per membrane. (A) Representative ﬁelds in normoxic and hypoxic culture. Scale bar=100 μm. (B)
Quantiﬁcation of invaded cells. Data expressed as average cell number per ﬁeld. ⁎Pb0.05 (n=7). (C) For migration studies, cells were grown to conﬂuence before creating a uniform
scratch wound and incubating in collagen and normoxia/hypoxia for a further 48 h. Representative image of wound assay after 48 h, shows cell migration into denuded wound area
in normoxia and hypoxia (original magniﬁcation ×40). (D). Quantiﬁcation of migrated cells. Data expressed as number of cells migrated to or further than 500 μm per mmwound
width. NS=not signiﬁcant (n=5). (E). Co-localisation of α-SMA (red) and vimentin (green) following 48 h of culture as seen by immunoﬂuorescence microscopy. Nuclei stained
with DAPI (blue). Scale bar=50 μm. (F). 7-day proliferation proﬁle of cells cultured in normoxia (solid line) and hypoxia (hashed line) in 0.5% and 10% FCS.
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Hypoxia was reported to reduce membrane-associated MT1-MMP in
isolated porcine ventricular myocytes [36], but was increased in a
breast cancer cell line [32], emphasising a role of MT1-MMP as a key
regulator of cellular invasion.
In direct contrast to previous reports in other cell types, chronic
hypoxia signiﬁcantly attenuatedmyoﬁbroblast invasion in the present
study. The reduced availability of membrane-associated MT1-MMP
would be anticipated to prohibit ternary complex formation and thus
lessen MMP-2 activation, accounting for the signiﬁcant inhibition of
invasion. We therefore demonstrated that transfection of myoﬁbro-
blasts withMMP-2 siRNA reduced total MMP-2 secretion; additionallytransfection with MT1-MMP siRNA resulted in both reduced mem-
brane expression of MT1-MMP and reduced MMP-2 activation.
Together these observations clearly delineate an essential role for
both molecules in the mechanism of MMP-2 activation in human
cardiac myoﬁbroblasts. We therefore performed mechanistic and
functional studies in parallel and conﬁrmed that cardiac myoﬁbroblast
invasion was unequivocally dependent on MT1-MMP. These ﬁndings
are in agreement with reports in other ﬁbroblastic cell types [37–40].
Our study also indicated that knockdown of MMP-2 inhibited invasion
as in human mesenchymal stem cells [38]. Conversely, others have
reported that MMP-2 siRNA did not attenuate invasion by HT-1080
cells [39].
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data indicated that chemotaxis (migration) can proceed indepen-
dently of changes in oxygen tension. Despite the lack of effect of
hypoxia on myoﬁbroblast migration, we did however observe a
consistent attenuation of active MMP-2 in ﬁbroblast-conditioned
medium from these assays. Similarly, using MMP-2 siRNA or MT1-
MMP siRNA-transfected cells, migrationwas not different from that of
mock-transfected cells. Our results concur with a study reporting that
migration of dermal ﬁbroblasts from MT1-MMP null mice was
comparable with those of wild-type mice [39]. However, again cell
type differences are reported with MT1-MMP knockdown decreasing
migration in HT-1080 cells [40].
In the present study, membrane expression of active MT1-MMP in
human cardiac myoﬁbroblasts was pivotal for hypoxic modulation of
both MMP-2 activation and cellular invasion. Hypoxia did not affect
MT1-MMP gene expression and hence must modulate its post-
transcriptional regulation. Potential targets for hypoxic regulation of
MT1-MMP are many, and include activation of the proenzyme by
proprotein convertases [41], membrane localisation, shedding, degra-
dation and MT1-MMP phosphorylation [42,43]. The activity of furin,
the proprotein convertase responsible for MT1-MMP activation, was
increased under hypoxic conditions and therefore could not be
accountable for the decreased levels of MT1-MMP (data not shown).Fig. 5. Effect of MMP-2 and MT1-MMP gene silencing on MMP-2 secretion and activatio
transfected cardiac myoﬁbroblasts were cultured in collagen for 48 h. Functional assay
myoﬁbroblasts. (A) Representative zymography of conditioned media collected at 48 h. (B) D
MT1-MMP expression determined by ELISA. ⁎⁎⁎Pb0.01 (n=5). (D) Densitometric quan
Quantiﬁcation of invaded cells, ⁎⁎Pb0.01, ⁎⁎⁎Pb0.001, (n=6). (F) Quantiﬁcation of migrateSimilarly the amount of soluble (“shed”) MT1-MMP in myoﬁbroblast-
conditioned media was not enhanced by chronic hypoxia (data not
shown). Lysosomal inhibition of MT1-MMP degradation with baﬁlo-
mycin-A1 led to a concentration-dependent increase in MMP-2
activation, as expected. However, this augmentation was observed
under both normoxic and hypoxic conditions, thereby ruling out
increased lysosomal activity as the mediator of hypoxia-induced
decrease in membrane-associatedMT1-MMP. Taken together our data
suggest that impairment of MT1-MMP protein translation is the most
likely target of hypoxia, thereby reducing its availability for ternary
complex formation, and consequent inhibition of MMP-2 activation.
Hypoxia is only one of numerous cues that inﬂuence cardiacmatrix
remodelling through effects onMMPs, and although our current study
investigated hypoxia per se, ischaemia-reperfusion injury is another
key regulator of MMP activity that modulates its effects through
alternative mechanism(s) [44]. Inﬂammatory mediators released
early after MI also play key roles. For example, TNFα modulates
long-term remodelling and ventricular dysfunction via increased
MMP-2 activity [45]. In contrast, TGFβ may only play a short-term
role; murine studies have reported that anti-TGFβ therapy prior to
experimental MI decreased collagen I and MMP-9 mRNA expression
after 3 days, but was ineffective by 8 weeks [46]. Activation of MMP-2
post-MI can have positive or negative effects that appear to be speciesn, and myoﬁbroblast function. For MMP quantiﬁcation, mock-transfected and siRNA-
s were performed in parallel using mock-transfected and siRNA-transfected cardiac
ensitometric analysis of MMP-2, NS=not signiﬁcant, ⁎⁎Pb0.01 (n=5). (C) Membrane
tiﬁcation of active MMP-2 relative to mock-transfected cells. ⁎⁎Pb0.01 (n=5). (E)
d cells. NS=not signiﬁcant (n=6).
398 K. Riches et al. / Journal of Molecular and Cellular Cardiology 47 (2009) 391–399dependent. For example, MMP-2 knockout rats exhibit preserved
cardiac function after MI suggesting that excessive MMP-2 activation
is deleterious [45]. In contrast, diabetic mice display reduced cardiac
expression of both MMP-2 and MT1-MMP and increased ﬁbrosis
suggesting that increased MMP-2 activation plays a positive role [47].
Also worthy of note is that the time course of MMP-2 activation post-
MI is variable between species; reportedly within 3 h in sheep infarct
zone [48], but not evident in the mouse until 4 days post-MI [49].
In conclusion, impaired cardiac myoﬁbroblast invasion in vivo as a
direct result of a period of oxygen deprivation may have deleterious
sequelae on the myocardium by delaying early, adaptive remodelling
following MI. Taking into account our own and previously published
studies, it is clearly evident that species and cell-type variation is a
major determinant of cellular responses to distinct stimuli. The
multiplicity of reported differences between studies (for review see
[50]) underscores the importance of selecting as far as possible,
appropriate experimental models. Such considerations are of direct
relevance to human disease, and our use of atrial-derived myoﬁbro-
blasts may have imposed some constraint on the present study.
Canine atrial and ventricular cells are claimed to exhibit inherent
differences [51], but importantly, the behaviour of human atrial and
ventricular cells has been reported to be similar [52]. The study
described here, by the use of cardiac myoﬁbroblasts from a series of
patients in well established laboratory models of migration and
invasion, endeavours to represent the in vivo scenario in man.
Understanding the mechanisms of the effects of hypoxia on human
cardiac myoﬁbroblast function may ultimately reveal potential novel
targets amenable to therapeutic manipulation.
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